search
Back to results

Cryosurgery and Cream Combination for Actinic Keratosis

Primary Purpose

Actinic Keratosis

Status
Completed
Phase
Phase 3
Locations
United States
Study Type
Interventional
Intervention
Carac Cream
Placebo Cetaphil cream
Sponsored by
Wake Forest University Health Sciences
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Actinic Keratosis focused on measuring Wake Forest, Actinic Keratosis, Cryosurgery, Cream

Eligibility Criteria

18 Years - 90 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Must be male or female and at least 18 years of age. Each subject must demonstrate good health as determined by a baseline medical history.
  • Female subjects myst be of either non-childbearing potential, or childbearing potential provided: negative urine pregnancy test and using two acceptable methods of effective contraception (abstinence, birth control pills.patch, DepoProvera, tubal ligation, vasectomy of the partner in a monogamous relationship, condoms and spermicidal form or gel and/or cervical cap or sponge), as determined by the investigator
  • At least eight clinically typical, visible and discrete AK lesions within the treatment area on the face or balding scalp
  • Subjects must be able and willing to comply with study procedures and have provided written informed consent.

Exclusion Criteria:

  • Cosmetic or therapeutic procedures (e.g., use of liquid nitrogen, surgical excision, curettage, dermabrasion, medium or greater depth chemical peel, laser resurfacing) within the selected treatment area in the previous four weeks.
  • Treatment with systemic medications that suppress the immune system within the previous four weeks.
  • Field treatments with topical 5-FU, imiquimod, diclofenac, or photodynamic therapy, or more widespread field treatment with dermabrasion, medium or greater depth chemical peel, or laser resurfacing within the previous six months.
  • Any known dihydropyrimidine dehydrogenase enzyme deficiency.
  • In addition, subjects who have any skin condition or disease that may require concurrent therapy or may confound the evaluation as determined by the investigator, or a history of hypersensitivity to any of the formulation components will be excluded from study.
  • Subjects may not use other topical agents such as glycolic acid products, alpha-hydroxy acid products, retinoids and chemical peel agents on teh treatment area while on study. The use of these products are not allowed four weeks prior to study enrollment. Introduction of any other prescription medication, topical or systemic for actinic keratosis while participating in the study is not permitted.
  • Pregnant women, women who are breast feeding, or women of childbearing potential who are not practicing two acceptable methods of effective contraception.

Sites / Locations

  • Wake Forest University Health Sciences Department of Dermatology

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

Group 1 Carac (fluorouracil) 0.5% cream

Group 2 Placebo

Arm Description

Carac cream (fluorouracil) 0.5% applied daily on the face for one week

Placebo Cetaphil cream applied daily on the face for one week

Outcomes

Primary Outcome Measures

Number Participants With 100% Clearance
The primary endpoint is number of participants that receive 100% clearance of AK lesions from treatment initiation to end of treatment

Secondary Outcome Measures

Number of Participants With 75% Clearance
The secondary endpoint is number of participants that receive 75 % clearance of

Full Information

First Posted
September 8, 2011
Last Updated
July 30, 2018
Sponsor
Wake Forest University Health Sciences
search

1. Study Identification

Unique Protocol Identification Number
NCT03037541
Brief Title
Cryosurgery and Cream Combination for Actinic Keratosis
Official Title
A Single-Center, Randomized, Single-Blinded, Placebo-Controlled Trial on the Efficacy of Cryosurgery and 5-Fluorouracil 0.5% Cream Combination Therapy for the Treatment of Actinic Keratosis
Study Type
Interventional

2. Study Status

Record Verification Date
July 2018
Overall Recruitment Status
Completed
Study Start Date
January 5, 2011 (Actual)
Primary Completion Date
October 29, 2013 (Actual)
Study Completion Date
October 29, 2013 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Wake Forest University Health Sciences

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Carac 0.5% cream is approved for daily topical treatment of AK's for up to four weeks as tolerated, though local irritation often occurs within the first week of treatment and increases in a dose-dependent manner. In this study, the investigators will examine the combination of standard cryosurgery treatment followed by a shortened course of topical fluorouracil cram. The investigators anticipate that a one week treatment course will maintain overall effectiveness when combined with previous cryosurgery, but will reduce the overall adverse effects of topical therapy due to the reduced treatment time and the presence of fewer baseline lesions to treat. This treatment approach may provide a more acceptable risk/benefit ratio option for patients with more extensive disease and simplify standard combination treatment options. The primary objective is to evaluate the efficacy of combination cryosurgery and 5-fluorouracil0.5% cream, compared to combination cryosurgery and placebo in the treatment of actinic keratosis lesions. The efficacy of this combination therapy will be evaluated by assessing AK lesion clearance. The primary efficacy parameter will be 10% clearance of all AK lesions from treatment initiation to end-of-treatment.
Detailed Description
This is a randomized (1:1), single-blind, placebo controlled, single center prospective study. Subjects will first undergo cryosurgery of all clinically apparent AK lesions, limited to the face or balding scalp. Three weeks after cryosurgery, subjects will then be randomized (1:1 according to standard randomization tables) and directed to apply either Carac 0.5% cream or placebo cream (Cetaphil Cream) to the face or balding scalp at bedtime for seven consecutive days, washed off each following morning. Each does of study cream will be applied at approximately the same time of day and will remain on the skin for approximately eight hours. Subject evaluation, Investigator Global Assessments, Quality of Life lesion counts and photography shall be performed at Baseline. At Week 3, study drug will be dispensed and the global assessments and assessment of improvement will be performed. A Medication Tolerability Assessment will occur at Week 4 when the study drug will be returned. Investigator Global Assessment, lesion count, Global Assessment of Improvement and Quality of Life will be measured at Week 8 and Week 26 (or end of study). Photography will be done at Week 26 or end of study.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Actinic Keratosis
Keywords
Wake Forest, Actinic Keratosis, Cryosurgery, Cream

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
Investigator
Allocation
Randomized
Enrollment
60 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Group 1 Carac (fluorouracil) 0.5% cream
Arm Type
Experimental
Arm Description
Carac cream (fluorouracil) 0.5% applied daily on the face for one week
Arm Title
Group 2 Placebo
Arm Type
Placebo Comparator
Arm Description
Placebo Cetaphil cream applied daily on the face for one week
Intervention Type
Drug
Intervention Name(s)
Carac Cream
Intervention Description
Carac Cream will be used once daily for seven consecutive days
Intervention Type
Drug
Intervention Name(s)
Placebo Cetaphil cream
Other Intervention Name(s)
Cetaphil
Intervention Description
Placebo Cetaphil Cream will be used once daily for seven consecutive days
Primary Outcome Measure Information:
Title
Number Participants With 100% Clearance
Description
The primary endpoint is number of participants that receive 100% clearance of AK lesions from treatment initiation to end of treatment
Time Frame
24 weeks
Secondary Outcome Measure Information:
Title
Number of Participants With 75% Clearance
Description
The secondary endpoint is number of participants that receive 75 % clearance of
Time Frame
24 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
90 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Must be male or female and at least 18 years of age. Each subject must demonstrate good health as determined by a baseline medical history. Female subjects myst be of either non-childbearing potential, or childbearing potential provided: negative urine pregnancy test and using two acceptable methods of effective contraception (abstinence, birth control pills.patch, DepoProvera, tubal ligation, vasectomy of the partner in a monogamous relationship, condoms and spermicidal form or gel and/or cervical cap or sponge), as determined by the investigator At least eight clinically typical, visible and discrete AK lesions within the treatment area on the face or balding scalp Subjects must be able and willing to comply with study procedures and have provided written informed consent. Exclusion Criteria: Cosmetic or therapeutic procedures (e.g., use of liquid nitrogen, surgical excision, curettage, dermabrasion, medium or greater depth chemical peel, laser resurfacing) within the selected treatment area in the previous four weeks. Treatment with systemic medications that suppress the immune system within the previous four weeks. Field treatments with topical 5-FU, imiquimod, diclofenac, or photodynamic therapy, or more widespread field treatment with dermabrasion, medium or greater depth chemical peel, or laser resurfacing within the previous six months. Any known dihydropyrimidine dehydrogenase enzyme deficiency. In addition, subjects who have any skin condition or disease that may require concurrent therapy or may confound the evaluation as determined by the investigator, or a history of hypersensitivity to any of the formulation components will be excluded from study. Subjects may not use other topical agents such as glycolic acid products, alpha-hydroxy acid products, retinoids and chemical peel agents on teh treatment area while on study. The use of these products are not allowed four weeks prior to study enrollment. Introduction of any other prescription medication, topical or systemic for actinic keratosis while participating in the study is not permitted. Pregnant women, women who are breast feeding, or women of childbearing potential who are not practicing two acceptable methods of effective contraception.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Joseph Jorizzo, MD
Organizational Affiliation
Wake Forest University Health Sciences
Official's Role
Principal Investigator
Facility Information:
Facility Name
Wake Forest University Health Sciences Department of Dermatology
City
Winston-Salem
State/Province
North Carolina
ZIP/Postal Code
27157
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Cryosurgery and Cream Combination for Actinic Keratosis

We'll reach out to this number within 24 hrs